275 related articles for article (PubMed ID: 23774431)
1. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.
Chang KC; Yew WW; Tam CM; Leung CC
Antimicrob Agents Chemother; 2013 Sep; 57(9):4097-104. PubMed ID: 23774431
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand.
Roongruangpitayakul C; Chuchottaworn C
J Med Assoc Thai; 2013 Oct; 96(10):1273-82. PubMed ID: 24350407
[TBL] [Abstract][Full Text] [Related]
3. Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
Fox GJ; Benedetti A; Cox H; Koh WJ; Viiklepp P; Ahuja S; Pasvol G; Menzies D;
Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049171
[TBL] [Abstract][Full Text] [Related]
4. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
[TBL] [Abstract][Full Text] [Related]
5. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.
Cox H; Ford N
Int J Tuberc Lung Dis; 2012 Apr; 16(4):447-54. PubMed ID: 22325685
[TBL] [Abstract][Full Text] [Related]
6. Linezolid in the treatment of MDR-TB: a retrospective clinical study.
Xu HB; Jiang RH; Li L; Xiao HP
Int J Tuberc Lung Dis; 2012; 16(3):358-63. PubMed ID: 22640450
[TBL] [Abstract][Full Text] [Related]
7. [Present and future in the use of anti-tubercular drugs].
Didilescu C; Craiova UM
Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
[TBL] [Abstract][Full Text] [Related]
8. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
Migliori GB; Eker B; Richardson MD; Sotgiu G; Zellweger JP; Skrahina A; Ortmann J; Girardi E; Hoffmann H; Besozzi G; Bevilacqua N; Kirsten D; Centis R; Lange C;
Eur Respir J; 2009 Aug; 34(2):387-93. PubMed ID: 19282348
[TBL] [Abstract][Full Text] [Related]
9. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations.
Garcia-Prats AJ; Rose PC; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2014 Mar; 94(2):93-104. PubMed ID: 24388605
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.
Gopal M; Padayatchi N; Metcalfe JZ; O'Donnell MR
Int J Tuberc Lung Dis; 2013 Aug; 17(8):1001-7. PubMed ID: 23541151
[TBL] [Abstract][Full Text] [Related]
11. Linezolid in the treatment of multidrug-resistant tuberculosis.
Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Sotgiu G; Centis R; D'Ambrosio L; Alffenaar JW; Anger HA; Caminero JA; Castiglia P; De Lorenzo S; Ferrara G; Koh WJ; Schecter GF; Shim TS; Singla R; Skrahina A; Spanevello A; Udwadia ZF; Villar M; Zampogna E; Zellweger JP; Zumla A; Migliori GB
Eur Respir J; 2012 Dec; 40(6):1430-42. PubMed ID: 22496332
[TBL] [Abstract][Full Text] [Related]
13. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
[TBL] [Abstract][Full Text] [Related]
14. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
15. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
; Ahmad N; Ahuja SD; Akkerman OW; Alffenaar JC; Anderson LF; Baghaei P; Bang D; Barry PM; Bastos ML; Behera D; Benedetti A; Bisson GP; Boeree MJ; Bonnet M; Brode SK; Brust JCM; Cai Y; Caumes E; Cegielski JP; Centis R; Chan PC; Chan ED; Chang KC; Charles M; Cirule A; Dalcolmo MP; D'Ambrosio L; de Vries G; Dheda K; Esmail A; Flood J; Fox GJ; Fréchet-Jachym M; Fregona G; Gayoso R; Gegia M; Gler MT; Gu S; Guglielmetti L; Holtz TH; Hughes J; Isaakidis P; Jarlsberg L; Kempker RR; Keshavjee S; Khan FA; Kipiani M; Koenig SP; Koh WJ; Kritski A; Kuksa L; Kvasnovsky CL; Kwak N; Lan Z; Lange C; Laniado-Laborín R; Lee M; Leimane V; Leung CC; Leung EC; Li PZ; Lowenthal P; Maciel EL; Marks SM; Mase S; Mbuagbaw L; Migliori GB; Milanov V; Miller AC; Mitnick CD; Modongo C; Mohr E; Monedero I; Nahid P; Ndjeka N; O'Donnell MR; Padayatchi N; Palmero D; Pape JW; Podewils LJ; Reynolds I; Riekstina V; Robert J; Rodriguez M; Seaworth B; Seung KJ; Schnippel K; Shim TS; Singla R; Smith SE; Sotgiu G; Sukhbaatar G; Tabarsi P; Tiberi S; Trajman A; Trieu L; Udwadia ZF; van der Werf TS; Veziris N; Viiklepp P; Vilbrun SC; Walsh K; Westenhouse J; Yew WW; Yim JJ; Zetola NM; Zignol M; Menzies D
Lancet; 2018 Sep; 392(10150):821-834. PubMed ID: 30215381
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
[No Abstract] [Full Text] [Related]
17. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?
Chang KC; Yew WW; Cheung SW; Leung CC; Tam CM; Chau CH; Wen PK; Chan RC
Antimicrob Agents Chemother; 2013 Jul; 57(7):3445-9. PubMed ID: 23650165
[TBL] [Abstract][Full Text] [Related]
18. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.
Koh WJ; Kang YR; Jeon K; Kwon OJ; Lyu J; Kim WS; Shim TS
J Antimicrob Chemother; 2012 Jun; 67(6):1503-7. PubMed ID: 22403262
[TBL] [Abstract][Full Text] [Related]
19. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
20. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
